Johan Areberg

798 total citations
35 papers, 604 citations indexed

About

Johan Areberg is a scholar working on Pharmacology, Psychiatry and Mental health and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Johan Areberg has authored 35 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 12 papers in Psychiatry and Mental health and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Johan Areberg's work include Treatment of Major Depression (13 papers), Electroconvulsive Therapy Studies (7 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Johan Areberg is often cited by papers focused on Treatment of Major Depression (13 papers), Electroconvulsive Therapy Studies (7 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Johan Areberg collaborates with scholars based in Denmark, Sweden and United States. Johan Areberg's co-authors include Birgitte Søgaard, George G. Nomikos, Grace Chen, Kristina Norrgren, Sören Mattsson, Anders Johnsson, Himanshu Naik, Grace Chen, S. Mattsson and Tore Bjerregaard Stage and has published in prestigious journals such as Annals of the New York Academy of Sciences, CHEST Journal and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Johan Areberg

34 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan Areberg Denmark 16 266 113 91 89 78 35 604
Ewa Wajs Belgium 19 325 1.2× 78 0.7× 23 0.3× 78 0.9× 132 1.7× 46 1.4k
Nikolaus Freymann Germany 10 86 0.3× 120 1.1× 97 1.1× 20 0.2× 50 0.6× 12 511
Adriaan Cleton United States 19 99 0.4× 394 3.5× 90 1.0× 29 0.3× 26 0.3× 58 978
Göran Westerberg Sweden 22 125 0.5× 86 0.8× 174 1.9× 40 0.4× 53 0.7× 46 1.1k
Ikuo Nomura Japan 16 130 0.5× 180 1.6× 12 0.1× 107 1.2× 56 0.7× 41 754
Tanja Veselinović Germany 14 82 0.3× 249 2.2× 86 0.9× 34 0.4× 50 0.6× 41 546
C. Dubruc France 17 103 0.4× 88 0.8× 24 0.3× 75 0.8× 9 0.1× 38 670
John Panagides United States 22 446 1.7× 1.0k 9.0× 31 0.3× 91 1.0× 69 0.9× 71 1.5k
Ahmed Elkashef United States 8 56 0.2× 344 3.0× 121 1.3× 22 0.2× 38 0.5× 23 584
Joseph H. Krushinski United States 18 268 1.0× 130 1.2× 28 0.3× 26 0.3× 25 0.3× 38 1.2k

Countries citing papers authored by Johan Areberg

Since Specialization
Citations

This map shows the geographic impact of Johan Areberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Areberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Areberg more than expected).

Fields of papers citing papers by Johan Areberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Areberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Areberg. The network helps show where Johan Areberg may publish in the future.

Co-authorship network of co-authors of Johan Areberg

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Areberg. A scholar is included among the top collaborators of Johan Areberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Areberg. Johan Areberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Areberg, Johan, et al.. (2024). Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies. Basic & Clinical Pharmacology & Toxicology. 135(4). 512–522. 1 indexed citations
2.
Rode, Frederik, Christoffer Bundgaard, Johan Areberg, et al.. (2024). Stress-free blood sampling in minipigs: A novel method for assessing 24-h cortisol profiles and drug effects on diurnal and ultradian rhythms. Journal of Pharmacological and Toxicological Methods. 127. 107504–107504. 1 indexed citations
3.
Areberg, Johan, et al.. (2023). Does ethnicity impact CYP2D6 genotype–phenotype relationships?. Clinical and Translational Science. 16(6). 1012–1020. 8 indexed citations
4.
Smith, Robert L., et al.. (2021). Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Clinical Pharmacokinetics. 60(11). 1475–1486. 1 indexed citations
5.
Vieta, Eduard, et al.. (2019). Intravenous vortioxetine to accelerate onset of effect in major depressive disorder. International Clinical Psychopharmacology. 34(4). 153–160. 11 indexed citations
6.
Wang, Gang, et al.. (2019). Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. Advances in Therapy. 36(11). 3134–3146. 9 indexed citations
7.
Findling, Robert L., Adelaide S. Robb, Melissa P. DelBello, et al.. (2017). Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. Journal of Child and Adolescent Psychopharmacology. 27(6). 526–534. 15 indexed citations
8.
Chen, Grace, et al.. (2017). Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clinical Pharmacokinetics. 57(6). 673–686. 104 indexed citations
9.
Naik, Himanshu, Majid Vakilynejad, Grace Chen, et al.. (2015). A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic & Clinical Pharmacology & Toxicology. 118(5). 344–355. 8 indexed citations
10.
Norrgren, Kristina, Sven Björkman, Johan Areberg, et al.. (2006). Comparative Renal, Hepatic, and Bone Marrow Toxicity of Cisplatin and Radioactive Cisplatin ( 191 Pt) in Wistar Rats. Cancer Biotherapy and Radiopharmaceuticals. 21(5). 528–534. 16 indexed citations
11.
Areberg, Johan, et al.. (2006). The pharmacokinetics of escitalopram in patients with hepatic impairment. The AAPS Journal. 8(1). E14–E19. 23 indexed citations
12.
Areberg, Johan, et al.. (2005). Population Biokinetic Modeling of Thyroid Uptake and Retention of Radioiodine. Cancer Biotherapy and Radiopharmaceuticals. 20(1). 1–10. 10 indexed citations
13.
Norrgren, Kristina, et al.. (2003). Accuracy of the Quantification of Organ Activity from Planar Gamma Camera Images. Cancer Biotherapy and Radiopharmaceuticals. 18(1). 125–131. 30 indexed citations
14.
Piitulainen, Eeva, et al.. (2002). Nutritional Status and Muscle Strength in Patients with Emphysema and Severe α1-Antitrypsin Deficiency. CHEST Journal. 122(4). 1240–1246. 21 indexed citations
15.
Areberg, Johan, Johan Wennerberg, Anders Johnsson, Kristina Norrgren, & Sören Mattsson. (2001). Antitumor effect of radioactive cisplatin (191Pt) on nude mice. International Journal of Radiation Oncology*Biology*Physics. 49(3). 827–832. 30 indexed citations
16.
Albertsson, Maria, et al.. (2000). The Prognostic Value of Body Protein in Patients with Lung Cancer. Annals of the New York Academy of Sciences. 904(1). 584–591. 34 indexed citations
17.
Areberg, Johan, Anders Johnsson, & Johan Wennerberg. (2000). In vitro toxicity of 191Pt-labeled cisplatin to a human cervical carcinoma cell line (ME-180). International Journal of Radiation Oncology*Biology*Physics. 46(5). 1275–1280. 16 indexed citations
18.
Areberg, Johan, Kristina Norrgren, & S. Mattsson. (1999). Absorbed doses to patients from 191Pt-, 193mPt- and 195mPt-cisplatin. Applied Radiation and Isotopes. 51(5). 581–586. 17 indexed citations
19.
Areberg, Johan, et al.. (1998). Body protein as a prognostic instrument for cancer patients?. Applied Radiation and Isotopes. 49(5-6). 639–641. 1 indexed citations
20.
Areberg, Johan, et al.. (1998). Only a temporary increase of the amount of body protein during long-term treatment with growth-hormone (GH) of adults with GH-deficiency (GHD). Applied Radiation and Isotopes. 49(5-6). 667–669. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ewa Wajs Breakdown of academic impact, for papers by Nikolaus Freymann Breakdown of academic impact, for papers by Adriaan Cleton Breakdown of academic impact, for papers by Göran Westerberg Breakdown of academic impact, for papers by Ikuo Nomura Breakdown of academic impact, for papers by Tanja Veselinović Breakdown of academic impact, for papers by C. Dubruc Breakdown of academic impact, for papers by John Panagides Breakdown of academic impact, for papers by Ahmed Elkashef Breakdown of academic impact, for papers by Joseph H. Krushinski
Rankless by CCL
2026